{"entity":{"id":"jounce-therapeutics","kind":"company","name":"Jounce Therapeutics","aka":["Jounce Therapeutics, Inc."],"tldr":"Jounce Therapeutics developed treatments that help the immune system attack cancer, along with tests to predict who would benefit. Concentra Biosciences bought it in 2023.","summary":"Jounce Therapeutics was a clinical-stage immunotherapy company focused on discovering and developing cancer immunotherapies and predictive biomarkers, listed on Nasdaq as JNCE. On 3 May 2023 Concentra Biosciences, LLC completed a tender offer for all Jounce shares at $1.85 a share in cash plus a non-tradeable contingent value right, then merged its subsidiary into Jounce, making Jounce a wholly owned Concentra subsidiary. Jounce's shares stopped trading on Nasdaq.","asOf":"2026-11-04","links":[{"label":"Closing of tender offer (SEC exhibit, 3 May 2023)","url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000084/jnce-exhibit991.htm"},{"label":"Third Rock Ventures portfolio entry","url":"https://www.thirdrockventures.com/portfolio/jounce"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Concentra Biosciences is not a company record in OnCo, so acquiredBy is not set.","Named product candidates are not stated in the sources read; none recorded.","Founding year not stated (2013 is Third Rock's year of investment)."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","stage":"acquired","investors":["third-rock-ventures"],"funding":[]},"route":"/companies/jounce-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"company":[{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/"}]}}